Aromatase inhibitors for breast cancer

Reviews in Endocrine and Metabolic Disorders

Volumn 8, Issue 3, 2007, Pages 215-228

  Briest, Susanne ^a,b   Davidson, Nancy E ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Endocrine treatment; Estrogen receptor; Hormonal therapy; Postmenopausal

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ATAMESTANE; EXEMESTANE; GOSERELIN; LETROZOLE; MEGESTROL ACETATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE; TRIPTORELIN; ZOLEDRONIC ACID;

ANGINA PECTORIS; ARTHRALGIA; ARTHRITIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM CANCER; FRACTURE; HEART FAILURE; HEART INFARCTION; HIP FRACTURE; HORMONE RELEASE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; MEMORY DISORDER; METASTASIS; MONOTHERAPY; MYALGIA; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PREDICTOR VARIABLE; PREOPERATIVE PERIOD; PREOPERATIVE TREATMENT; REVIEW; SIDE EFFECT; SPINE FRACTURE; SWEATING; THROMBOEMBOLISM; TREATMENT RESPONSE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VEIN DISEASE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; POSTMENOPAUSE; TAMOXIFEN;

EID: 34948839919     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-007-9039-z     Document Type: Review

References (83)

1. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971;34:55-70.
2. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76(1):27-36.
3. Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol 2005;95 (1-5):113-9.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687-717.
5. Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS. The pharmacology of letrozole. J Steroid Biochem Mol Biol 2003;87(1):35-45.
6. Lonning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 1990;35(3-4):355-66.
7. Cash R, Brough AJ, Cohen MN, Satoh PS. Aminoglutethimide (elipten-ciba) as an inhibitor of adrenal steroidogenesis: Mechanism of action and therapeutic trial. J Clin Endocrinol Metab 1967;27(9):1239-48.
8. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A. 4- hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984;2(8414):1237-9.
9. Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM, et al. A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer 1990;65(6):1279-85.
10. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993;53(2):266-70.
11. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74(8):1286-91.
12. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4(9):2089-93.
13. Lonning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988; 35(6):685-710.
14. Bernardi A, Zamagni C, Di Fabrio F, Piana E, Martoni A, Vecchi F. Randomized comparative study on estrogen suppression induced by 3 different aromatase inhibitors in postmenopausal patients with advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:217 (abstract).
15. Goss PE. Breast cancer prevention-clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 2003;86(3-5):487-93.
16. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex study group. Cancer 1997;79(4):730-9.
17. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A(3):404-12.
18. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19(14):3357-66.
19. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16(2):453-61.
20. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The exemestane study group. J Clin Oncol 2000;18(7):1399-411.
21. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000;18(22):3748-57.
22. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex study group. J Clin Oncol 2000;18(22):3758-67.
23. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 2001;19(10):2596-606.
24. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14(9):1391-8.
25. Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)-A randomized phase III trial of the EORTC breast group (meeting abstracts). J Clin Oncol 2004;22(Suppl 14):515 (abstract).
26. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis. J Natl Cancer Inst 2006;98(18):1285-91.
27. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39(16):2318-27.
28. Mayordomo J, Llombart A, Martin M, Anton A, Barnadas A, Antolin et al. Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study (meeting abstracts). J Clin Oncol 2006;24(Suppl 18):638 (abstract).
29. Goss PE, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH, Blanchett D, et al. Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer (meeting abstracts). J Clin Oncol 2006;24(Suppl 18):LBA525.
30. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359(9324):2131-9.
31. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2.
32. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999;57(2):183-92.
33. Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian Breast and Colorectal Cancer Study Group trial 6. J Clin Oncol 2003;21(6):984-90.
34. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57.
35. Jones SE. Exemestane as adjuvant treatment of early breast cancer: Intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clin Breast Cancer 2006;6(Suppl 2):S41-4.
36. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Caroti C, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 2001;19(22):4209-15.
37. Brodie A. Aromatase inhibitor development and hormone therapy: A perspective. Semin Oncol 2003;30(4 Suppl 14):12-22.
38. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2(2):101-12.
39. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): A randomised controlled trial. Lancet 2007;369(9561):559-70.
40. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23(22):5138-47.
41. Boccardo F, Rubagotti A, Aldrighetti D, Buzzi F, Cruciani G, Farris A, et al. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma. Cancer 2007;109(6):1060-7.
42. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62.
43. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684-690.
44. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71.
45. Mamounas E, Jeong JH, Wickerham L, Smith R, Geyer C, Ganz P, et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): Intent-to treat analysis of NSABP B-33. Breast Cancer Res Treat 2006;100(Suppl 1):49 (abstract).
46. Jakesz R, Samonigg H, Greil R, Gnant M, Schmid M, Kwasny W, et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group trial 6a (ABCSG-6a) (meeting abstracts). J Clin Oncol 2005;23(Suppl 16) :527 (abstract).
47. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25(5):486-92.
48. Coombes RC, Paridaens R, Jassem J, Van de Velde CJ, Delozier T, Jones SE, et al.,. First mature analysis of the Intergroup Exemestane Study (meeting abstracts). J Clin Oncol 2006;24(Suppl 18):LBA527.
49. Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol 2006;17(7):10-4.
50. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, et al. Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study (meeting abstracts). J Clin Oncol 2006;24(Suppl 18):547 (abstract).
51. Ingle JN, Tu D, Pater, J, Martino S, Robert NJ, Muss HM, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006;99(3):295-300.
52. Preece PE, Wood RA, Mackie CR, Cuschieri A. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: A pilot study. Br Med J (Clin Res Ed) 1982;284(6319):869-70.
53. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24(12):1940-9.
54. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The Pre-operative "Arimidex" compared to Tamoxifen (PROACT) trial. Cancer 2006;106(10):2095-103.
55. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003;9(1):124-33.
56. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23(22):5108-16.
57. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001;12(11):1527-32.
58. Semiglazov V, Kletsel A, Semiglazov V, Zhiltzova E, Ivanov V, Dashyan G, et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) (meeting abstracts). J Clin Oncol 2005;23(16):530 (abstract).
59. Kendall A, Dowsett M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Relat Cancer 2006;13(3):827-37.
60. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6(10):798-808.
61. Coleman RE, Banks LM, Girgis S, Vrdoljak E, Fox J, Porter LS, et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) 2 year bone mineral density (BMD) and bone biomarker data. Breast Cancer Treat Res 2005;88(Suppl 1):5076, S35 (abstract).
62. McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A, Eastell R. The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women (meeting abstracts). J Clin Oncol 2006;24(Suppl 18):555 (abstract).
63. Mincey B, Duh M, Thomas S, Moyneur E, Marynchencko M, Boyce S, et al. Risk of cancer treatment-related osteoporosis and fractures among women with breast cancer receiving aromatase inhibitors (meeting abstracts). J Clin Oncol 2006;24(Suppl 18) :557 (abstract).
64. Brufsky A, Harker W, Beck J, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial (meeting abstracts). J Clin Oncol 2005;23(Suppl 16):533 (abstract).
65. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005;93(1):61-6.
66. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC trial 10951, 'randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004;15(2):211-7.
67. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23(28):6931-40.
68. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, On behalf of the ATAC Trialists Group. Quality of life of postmenopausal women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100(3):273-84.
69. Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, et al. Quality of life in the Intergroup Exemestane Study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24(6):910-7.
70. Jonat W, Pritchard KI, Sainsbury R, Klijn JG. Trends in endocrine therapy and chemotherapy for early breast cancer: A focus on the premenopausal patient. J Cancer Res Clin Oncol 2006;132(5):275-86.
71. Dowsett M, Doody D, Miall S, Howes A, English J, Coombes RC. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 1999;56(1):25-34.
72. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4.
73. Gnant M, Jakesz R, Mlineritsch B, Luschin-Ebengreuth G, Schmid M, Menzel C, et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen-bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res Treat 2004;88(Suppl 1):S8, 6 (abstract).
74. Smith IE, Dowsett M, Yap YS, Walsh G, Lonning PE, Santen RJ, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol 2006;24(16):2444-7.
75. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80(1):61-74.
76. Dowsett M, on Behalf of the ATAC Trialists Group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(Suppl 1):S7, 4 (abstract).
77. Dowsett M, Allred, DC on Behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006;100(Suppl 1):48 (abstract).
78. Hu JC, Mokbel K. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol 2001;27(4):335-7.
79. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808-16.
80. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005;23(3):619-29.
81. Radice D, Redaelli A. Breast cancer management: Quality-of-life and cost considerations. Pharmacoeconomics 2003;21(6):383-96.
82. Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006;17(2):217-25.
83. Leary A, Dowsett M. Combination therapy with aromatase inhibitors: The next era of breast cancer treatment? Br J Cancer 2006; 95(6):661-6.